Cencora (NYSE:COR) Trading Up 9.1% After Earnings Beat

Cencora, Inc. (NYSE:COR) rose 9.1% during trading on Thursday following a stronger than expected earnings report. The stock traded as high as $359.10 and last traded at $359.90. Approximately 383,655 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 1,195,642 shares. The stock had previously closed at $329.97.

The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same period last year, the business earned $3.73 EPS. Cencora’s revenue for the quarter was up 5.5% on a year-over-year basis.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be paid a $0.60 dividend. The ex-dividend date is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is presently 30.19%.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat on EPS and showed improving margins, with adjusted metrics and profit per share topping estimates — a sign the specialty medicines strategy is supporting profitability. Reuters: Cencora beats quarterly profit estimates
• Positive Sentiment: Management raised fiscal‑2026 operating income growth targets (11.5%–13.5%) and lifted the sales outlook while integrating the OneOncology acquisition, which supports medium‑term revenue and margin expansion expectations. MSN: Cencora outlines operating income growth while integrating OneOncology TipRanks: Completes OneOncology acquisition
• Positive Sentiment: Cencora completed the OneOncology acquisition, which management says will drive specialty oncology volume — a strategic growth catalyst. BusinessWire: Q1 results / OneOncology
• Neutral Sentiment: The board declared a $0.60 quarterly dividend (ex‑dividend Feb 13), a modest yield that signals confidence but is unlikely to move the stock materially.
• Neutral Sentiment: Revenue was up 5.5% year‑over‑year to $85.9B, showing underlying growth despite the near‑term noise; full earnings call transcript and slide deck are available for details. Seeking Alpha: Earnings call transcript
• Negative Sentiment: Revenue missed Street estimates by a small margin (~$86.12B expected vs. $85.9B reported); the top‑line miss triggered intra‑day selling and headlines emphasizing a revenue shortfall. MSN: Revenue miss MarketWatch: Falls on revenue miss
• Negative Sentiment: The stock underperformed peers in trading after results, suggesting investors favored cleaner top‑line beats across the sector and rotated away from even slight misses. MSN: Underperformance vs competitors
• Negative Sentiment: Market reaction reflects focus on near‑term revenue execution despite positive guidance — if upcoming quarters don’t show clear sales acceleration, sentiment could remain weak. Benzinga: Lifts sales outlook despite revenue miss

Analyst Ratings Changes

Several equities analysts have recently issued reports on COR shares. Mizuho boosted their price objective on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Barclays began coverage on shares of Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price target on the stock. Finally, Wells Fargo & Company increased their target price on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $394.75.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the sale, the chief executive officer directly owned 65,746 shares in the company, valued at approximately $24,105,113.44. This trade represents a 7.19% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 20,316 shares of company stock valued at $7,151,265. 0.38% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cencora

Several hedge funds and other institutional investors have recently modified their holdings of the business. Atlantic Edge Private Wealth Management LLC raised its holdings in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares during the last quarter. Oakworth Capital Inc. purchased a new stake in shares of Cencora in the fourth quarter valued at approximately $26,000. Archer Investment Corp lifted its position in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares in the last quarter. IAG Wealth Partners LLC purchased a new position in Cencora during the third quarter worth approximately $30,000. Finally, Vermillion & White Wealth Management Group LLC boosted its stake in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after buying an additional 43 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 9.5%

The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The business has a 50 day simple moving average of $346.43 and a 200-day simple moving average of $325.27. The firm has a market capitalization of $70.07 billion, a price-to-earnings ratio of 45.40, a P/E/G ratio of 1.72 and a beta of 0.68.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.